AnaptysBio (ANAB) said Wednesday that a phase 2b trial of its investigational drug rosnilimab to treat moderate-to-severe rheumatoid arthritis achieved its primary and secondary endpoints.
Patients in the study received either 100 milligram or 400 milligram doses of rosnilimab every four weeks, 600 milligrams every two weeks, or placebo, the company said.
The trial achieved its primary endpoint of a change from baseline for all three doses vs. placebo at week 12 and showed that the drug was safe and well-tolerated, the company said.
AnaptysBio shares were 23% higher in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.